PressJuly 10, 2024 Cybin Inc. Stands Strong As A Remaining Force To Prove Benefits Of Psychedelic Therapeutics ($CYBN)
PressJuly 9, 2024 Red Light Holland CTIO to Unveil Groundbreaking iMicroapp Research Findings to Prestigious Drug Science Consortium
PressJuly 8, 2024 Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
PressJuly 8, 2024 Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
PressJuly 8, 2024 Clearmind Medicine Inc. Announces Advancement in its Proprietary MEAI- Based Binge Behaviors Treatment
PressJuly 3, 2024 Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Health & ScienceJuly 2, 2024 Analysis Reveals the Most Significant Improvements From Psychedelic Use Apply To Single Individuals
Health & ScienceJuly 2, 2024 Lykos Therapeutics Responds to ICER’s Critique of MDMA Assisted Psychotherapy for PTSD
PressJuly 1, 2024 Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
PressJune 27, 2024 MindBio Therapeutics Corp. Reports Durability Data from Phase 2A Clinical Trials in Depressed Patients Testing MB22001
PressJune 27, 2024 Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists
PressJune 26, 2024 atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
